tiprankstipranks
Advertisement
Advertisement
Travere Therapeutics plans accounting leadership transition in 2026
PremiumCompany AnnouncementsTravere Therapeutics plans accounting leadership transition in 2026
25d ago
Travere Therapeutics price target raised to $65 from $56 at Guggenheim
Premium
The Fly
Travere Therapeutics price target raised to $65 from $56 at Guggenheim
1M ago
Travere Therapeutics price target raised to $61 from $55 at Wedbush
Premium
The Fly
Travere Therapeutics price target raised to $61 from $55 at Wedbush
1M ago
Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
PremiumMarket NewsMega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
2M ago
Travere Therapeutics says Filspari generally well tolerated in Phase 3 study
Premium
The Fly
Travere Therapeutics says Filspari generally well tolerated in Phase 3 study
2M ago
Travere Therapeutics price target raised to $62 from $59 at Citi
Premium
The Fly
Travere Therapeutics price target raised to $62 from $59 at Citi
2M ago
Ligand price target raised to $266 from $263 at BofA
PremiumThe FlyLigand price target raised to $266 from $263 at BofA
2M ago
Travere Therapeutics price target raised to $59 from $50 at BofA
Premium
The Fly
Travere Therapeutics price target raised to $59 from $50 at BofA
2M ago
Travere confirms Notice of Allowance from USPTO for Filspari patent application
Premium
The Fly
Travere confirms Notice of Allowance from USPTO for Filspari patent application
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100